InflaRx (NASDAQ:IFRX) Short Interest Update

InflaRx (NASDAQ:IFRX) saw a large decline in short interest in the month of February. As of February 29th, there was short interest totalling 293,900 shares, a decline of 9.3% from the February 14th total of 324,200 shares. Based on an average daily trading volume, of 278,300 shares, the days-to-cover ratio is currently 1.1 days.

Analysts Set New Price Targets

Separately, HC Wainwright lowered their price target on InflaRx from $9.00 to $8.00 and set a “buy” rating for the company in a report on Thursday, January 25th.

InflaRx Stock Down 5.1 %

Shares of NASDAQ IFRX traded down $0.08 during midday trading on Monday, hitting $1.50. The stock had a trading volume of 149,419 shares, compared to its average volume of 241,840. The company has a market capitalization of $67.05 million, a price-to-earnings ratio of -2.03 and a beta of 1.29. InflaRx has a 1-year low of $1.14 and a 1-year high of $7.25. The company has a fifty day moving average price of $1.63 and a 200 day moving average price of $1.96.

Hedge Funds Weigh In On InflaRx

Several hedge funds and other institutional investors have recently modified their holdings of the company. Suvretta Capital Management LLC raised its position in shares of InflaRx by 167.2% in the 2nd quarter. Suvretta Capital Management LLC now owns 5,733,910 shares of the company’s stock valued at $25,573,000 after purchasing an additional 3,587,670 shares in the last quarter. 683 Capital Management LLC acquired a new position in shares of InflaRx in the 2nd quarter valued at approximately $8,920,000. Point72 Asset Management L.P. bought a new stake in shares of InflaRx in the 2nd quarter valued at approximately $8,531,000. Woodline Partners LP bought a new stake in shares of InflaRx in the 2nd quarter valued at approximately $2,197,000. Finally, Schonfeld Strategic Advisors LLC bought a new stake in shares of InflaRx in the 2nd quarter valued at approximately $1,646,000. 48.23% of the stock is owned by institutional investors and hedge funds.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.